Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 12/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711711 | 1.00 | HSD11B1 (0.53) | HSD11B1EPHX2EPHX1CHRNB2CHRNB4 | |
| SCHEMBL18478535 | 1.00 | HSD11B1 (0.53) | HSD11B1EPHX2EPHX1CHRNB2CHRNB4 | |
| SCHEMBL18711710 | 1.00 | HSD11B1 (0.53) | HSD11B1EPHX2EPHX1CHRNB2CHRNB4 | |
| SCHEMBL6674224 | 0.87 | CHRNB2 (0.58) | HSD11B1EPHX2EPHX1CHRNB2CHRNB4 | |
| SCHEMBL6674226 | 0.87 | CHRNB2 (0.58) | HSD11B1EPHX2EPHX1CHRNB2CHRNB4 | |
| SCHEMBL6675552 | 0.87 | CHRNB2 (0.58) | HSD11B1EPHX2EPHX1CHRNB2CHRNB4 | |
| SCHEMBL11204345 | 0.85 | HSD11B1 (0.59) | HSD11B1EPHX2EPHX1CHRNB2CHRNB4 | |
| SCHEMBL11204341 | 0.85 | HSD11B1 (0.59) | HSD11B1EPHX2EPHX1CHRNB2CHRNB4 | |
| SCHEMBL17690703 | 0.84 | HSD11B1 (0.50) | HSD11B1EPHX2EPHX1CNR2MBTD1 | |
| SCHEMBL772491 | 0.83 | HSD11B1 (0.56) | HSD11B1CNR2MBTD1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-10328141-B2 | Synthetic vaccines against Streptococcus pneumoniae type 1 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20160346374-A1 | SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 1 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-12-01 | — | — | US | disclosed |
| US-8952176-B2 | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | BOEHRINGER MARKUS (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-1894919-B1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2012-03-28 | — | — | EP | disclosed |
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1894919-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F12, F11, F2 | HSD11B1 1716/4885EPHX2 809/4885EPHX1 1271/4885 |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | HSD3B1, NR5A1, HSD11B1 | HSD11B1 3/4885EPHX2 1668/4885EPHX1 1338/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | HSD11B1 600/4885EPHX2 2025/4885EPHX1 1254/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | HSD11B1 375/4885EPHX2 1398/4885EPHX1 950/4885 |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | F12, F11, F2 | HSD11B1 1716/4885EPHX2 809/4885EPHX1 1271/4885 |
| US-20160346374-A1 | SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 1 | NEU1, ALG1, CSGALNACT1 | HSD11B1 1935/4885EPHX2 4362/4885EPHX1 3959/4885 |
| US-10328141-B2 | Synthetic vaccines against Streptococcus pneumoniae type 1 | NEU1, ALG1, CSGALNACT1 | HSD11B1 1935/4885EPHX2 4362/4885EPHX1 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.